Dr. Geir Bjørklund, MD, has provided groundbreaking insights into the zinc (Zn) and copper (Cu) dynamics associated with autism spectrum disorder (ASD), featured in a recent interview in ARS Medica Tomitana, the official journal of Ovidius University of Constanta (Semenova, 2023).

Through international collaborations spanning various countries, Bjørklund’s research has uncovered compelling evidence of altered Zn and Cu levels in individuals with ASD. Elevated Cu levels appear to be correlated with increased symptom severity, suggesting a critical link to the neurobiological underpinnings of ASD.

In a discussion with Dr. Yuliya Semenova from Nazarbayev University School of Medicine, Dr. Bjørklund emphasized the pivotal role of metallothionein proteins in synaptic modulation within the GABAergic system, shedding light on ASD pathophysiology.

Advocating for future research that explores diverse biological mediums to assess trace element levels, Bjørklund’s work promises valuable insights into the interactions and dynamics of trace elements in ASD pathogenesis.

The interview also explores potential therapeutic implications, primarily focusing on the role of Zn supplementation in ASD treatment. Dr. Bjørklund underscores the necessity of monitoring both Cu and Zn levels during therapy to optimize outcomes.

Through collaborative efforts across international borders, Dr. Bjørklund’s research significantly advances the understanding of the role of Zn and Cu in ASD, emphasizing the global impact of this work. These findings underscore the need for a comprehensive approach to unraveling trace element intricacies in ASD, paving the way for innovative therapeutic strategies and improved patient outcomes.

Vital Press

Reference

Semenova Y. The zinc-copper connection in autism spectrum disorder: Pioneering work of Dr. Geir Bjørklund. ARS Medica Tomitana 2023; 29(4): 245-257. doi: 10.2478/arsm-2023-0036.